SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Select Medical Holdings Corporation (SEM) trades at a trailing P/E of 13.8, forward P/E of 13.0. Trailing earnings yield is 7.23%, forward earnings yield 7.68%. PEG 1.97. Graham Number is $20.95.
Criteria proven by this page:
- VALUE (80/100, Pass) — P/E is below market average (13.8); earnings yield beats bond yields (7.23%).
- Forward P/E 13.0 (down from trailing 13.8) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 1.97 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield 7.23% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 7.68% as earnings recover.
- Analyst consensus target $18.00 (+9.9% upside) — modest upside expected.
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
80/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
17/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SEM
Valuation Multiples
P/E (TTM)13.8
Forward P/E13.0
PEG Ratio1.97
Forward PEG1.97
P/B Ratio1.19
P/S Ratio0.37
EV/EBITDA10.8
Per Share Data
EPS (TTM)$1.18
Forward EPS (Est.)$1.26
Book Value / Share$16.48
Revenue / Share$44.15
FCF / Share$0.95
Yields & Fair Value
Earnings Yield7.23%
Forward Earnings Yield7.68%
Dividend Yield1.53%
Graham Number$20.95
SharesGrow IV$44.01 (+168.7%)
Analyst Target$18.00 (+9.9%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
7.9 |
-0.66 |
1.01 |
0.21 |
- |
| 2017 |
6.9 |
0.14 |
1.31 |
0.28 |
- |
| 2018 |
7.8 |
-0.38 |
1.17 |
0.21 |
- |
| 2019 |
11.0 |
0.24 |
2.12 |
0.30 |
- |
| 2020 |
7.5 |
0.29 |
1.82 |
0.35 |
- |
| 2021 |
5.1 |
0.09 |
1.86 |
0.33 |
2.45% |
| 2022 |
10.5 |
-0.18 |
1.49 |
0.26 |
3.88% |
| 2023 |
6.4 |
0.12 |
1.21 |
0.23 |
4.10% |
| 2024 |
11.4 |
-0.87 |
1.45 |
0.47 |
2.65% |
| 2025 |
12.5 |
-0.43 |
1.08 |
0.34 |
1.71% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.87 |
$4.29B |
$115.41M |
2.7% |
| 2017 |
$0.87 |
$4.44B |
$177.18M |
4% |
| 2018 |
$1.06 |
$5.08B |
$137.84M |
2.7% |
| 2019 |
$1.54 |
$5.45B |
$201.03M |
3.7% |
| 2020 |
$1.93 |
$5.53B |
$259M |
4.7% |
| 2021 |
$2.99 |
$6.2B |
$402.23M |
6.5% |
| 2022 |
$1.23 |
$6.33B |
$158.99M |
2.5% |
| 2023 |
$1.91 |
$6.66B |
$243.49M |
3.7% |
| 2024 |
$1.66 |
$5.19B |
$214.04M |
4.1% |
| 2025 |
$1.18 |
$5.45B |
$146.22M |
2.7% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$1.26 |
$1.24 – $1.29 |
$5.69B |
$5.62B – $5.73B |
4 |
| 2027 |
$1.39 |
$1.30 – $1.45 |
$5.97B |
$5.94B – $6B |
4 |
| 2028 |
$1.51 |
$1.23 – $1.78 |
$6.23B |
$6.2B – $6.26B |
2 |
